FDA Gives Okay For PTSD Sufferers To Start Ecstasy Trials

Jason Reynolds - Author

Sep. 10 2017, Updated 8:16 p.m. ET

There is great news for the nearly 5.2 million people in the United States that suffer from Post-Traumatic Stress Disorder (PTSD). The F00d and Drug Administration (FDA) has given their approval for 3-4 methylenedioxymethamphetamine (MDMA), better known as the street drug ecstasy, to be used in Phase 3 trials for the treatment of PTSD. The FDA gave the Breakthrough Therapy Designation to MDMA for the treatment of posttraumatic stress disorder.

Article continues below advertisement

The Phase 3 trials will be handled by the non-profit group Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS and the FDA have agreed on two upcoming Phase 3 trials under the Special Protocol Assessment Process to use MDMA in conjunction with traditional psychotherapy to treat severe PTSD. The combination uses three doses of MDMA as a pharmacological adjunct to assist traditional psychotherapy techniques.

When Will the Trials Begin?

The Breakthrough Therapy Designation indicates that the FDA has reviewed initial studies and agrees that this form of treatment may be better for some patients than traditional drugs.


Latest fda News and Updates

    © Copyright 2022 The Inquisitr. The Inquisitr is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.